

Heparin Cofactor II Conjugated Antibody

Catalog No: #C33652



Package Size: #C33652-AF350 100ul #C33652-AF405 100ul #C33652-AF488 100ul
 #C33652-AF555 100ul #C33652-AF594 100ul #C33652-AF647 100ul
 #C33652-AF680 100ul #C33652-AF750 100ul #C33652-Biotin 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description

Product Name	Heparin Cofactor II Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of total Heparin Cofactor II protein.
Immunogen Description	Synthesized peptide derived from internal of human Heparin Cofactor II.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	Heparin cofactor 2 [Precursor];Heparin cofactor II;HC-II;Protease inhibitor leuserpin 2;HLS2
Accession No.	Swiss-Prot#:P05546NCBI Gene ID:3053
Uniprot	P05546
GeneID	3053;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	57
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Product Description

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Background

Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner. Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.

Note: This product is for in vitro research use only